GPCR
Structure Therapeutics Inc.
$42.93
-0.85%
$3.1B
No data for this timeframe.
Vol
Market Cap$3.1B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$1.7B
Inst. Activity12 buys / 15 sells
Insider Activity0B / 1S
Insider Net $-$75.3K
Reddit Sentiment50° Neutral
SEC Reports4
Press Releases2
Recent Activity
Jun 11, 2026
SEC
A mixed institutional cluster in GPCR (2025-Q3) shows 4 buyers adding a net $6.0M against 3 sellers reducing by $51.6M.
INST-CLUSTER — Impact 5/10
Jun 5, 2026
fda
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
<p align="center"><em>Publication presented concurrently with oral presentation at</em><br><em> Amer
May 7, 2026
SEC
Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while announcing positive P
8-K — Impact 6/10
Apr 15, 2026
SEC
Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026.
8-K — Impact 3/10
Apr 15, 2026
Insider
Lang Matthew was granted 223,776 shares
COO & GC
Apr 15, 2026
Insider
Lang Matthew was granted 184,614 shares
COO & GC
Apr 14, 2026
Insider
FMR LLC sold 1,367 shares
10%+ Owner @ $55.07 ($75.3K)
Inst.
CAPITOLIS LIQUID GLOBAL MARKETS — ADD
1,151,300 shares ($55.5M)
Price Targets
$104.59
+143.6% upside
Strong Buy
Current $42.93
Low $69.50
Median $101.00
High $145.00
16 analysts
$69.50
$145.00
Analyst Ratings
8Strong Buy
14Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 27, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 27, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.38 | $-0.47 — $-0.20 | -6% YoY | 10 |
| Next Q | $-0.19 | $-0.49 — $2.03 | 49% YoY | 10 |
| Current FY | $-1.43 | $-1.93 — $1.25 | -79% YoY | 12 |
| Next FY | $-2.08 | $-3.08 — $-1.34 | -45% YoY | 11 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster in GPCR (2025-Q3) shows 4 buyers adding a net $6.0M against 3 sellers reducing by $51.6M.
Jun 11, 2026
MIXED
8-K
6/10
Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while announcing positive P
May 7, 2026
NEUTRAL
Press
2/10
Structure Therapeutics announced multiple presentations at the ADA 86th Scientific Sessions, including an oral presentat
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $405.0M | ADD |
| WELLINGTON MANAGEMENT GROUP LLP | $349.9M | ADD |
| Avoro Capital Advisors LLC | $316.0M | ADD |
| MORGAN STANLEY | $111.1M | DOUBLED |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $76.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 15, 2026 | Lang Matthew | A | $0.00 |
| Apr 15, 2026 | Lang Matthew | A | $0.00 |
| Apr 14, 2026 | FMR LLC | SELL | $75.3K |
| Mar 19, 2026 | Stevens Raymond | A | $0.00 |
| Mar 19, 2026 | Stevens Raymond | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $1.7B total value (35,826,151 shares) as of 2026-Q1. Top holders: FMR, WELLINGTON, Avoro. Net selling activity: 15 institutions trimmed/exited vs 12 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 8,403,449 | $405.0M | 23.3% | ADD +65.9% |
| 2 | WELLINGTON MANAGEMENT GROUP LLP | 7,260,287 | $349.9M | 20.1% | ADD +25.2% |
| 3 | Avoro Capital Advisors LLC | 6,555,555 | $316.0M | 18.2% | ADD +27.2% |
| 4 | MORGAN STANLEY | 2,305,457 | $111.1M | 6.4% | DOUBLED +261.4% |
| 5 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1,577,356 | $76.0M | 4.4% | ADD +88.0% |
| 6 | BAKER BROS. ADVISORS LP | 1,432,529 | $69.0M | 4.0% | — |
| 7 | CAPITOLIS LIQUID GLOBAL MARKETS LLC | 1,151,300 | $55.5M | 3.2% | ADD +31.1% |
| 8 | ALLIANCEBERNSTEIN L.P. | 638,813 | $44.4M | 2.6% | NEW |
| 9 | FRANKLIN RESOURCES INC | 531,595 | $25.6M | 1.5% | TRIM -38.9% |
| 10 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 467,800 | $22.5M | 1.3% | NEW |
| 11 | BlackRock, Inc. | 441,975 | $21.3M | 1.2% | ADD +62.9% |
| 12 | DEUTSCHE BANK AG\ | 331,867 | $16.0M | 0.9% | TRIM -60.5% |
| 13 | NATIONAL BANK OF CANADA /FI/ | 305,400 | $14.7M | 0.8% | ADD +84.3% |
| 14 | BALYASNY ASSET MANAGEMENT L.P. | 304,934 | $14.7M | 0.8% | ADD +41.0% |
| 15 | GOLDMAN SACHS GROUP INC | 260,543 | $12.6M | 0.7% | — |
| 16 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 254,969 | $12.3M | 0.7% | NEW |
| 17 | Pentwater Capital Management LP | 245,000 | $11.8M | 0.7% | NEW |
| 18 | BANK OF AMERICA CORP /DE/ | 227,132 | $10.9M | 0.6% | DOUBLED +617.0% |
| 19 | AMERIPRISE FINANCIAL INC | 219,516 | $10.6M | 0.6% | NEAR_EXIT -76.7% |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 206,700 | $10.0M | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | ADD | 878,300 | 1,151,300 | +31.1% | $55.5M | 2026-Q1 |
| FRANKLIN RESOURCES INC | TRIM | 870,582 | 531,595 | -38.9% | $25.6M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 841,162 | 331,867 | -60.5% | $16.0M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 216,199 | 304,934 | +41.0% | $14.7M | 2026-Q1 |
| Pentwater Capital Management LP | NEW | — | 245,000 | — | $11.8M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 31,678 | 227,132 | +617.0% | $10.9M | 2026-Q1 |
| Woodline Partners LP | ADD | 123,902 | 190,808 | +54.0% | $9.2M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | NEAR_EXIT | 5,090,148 | 150,817 | -97.0% | $7.3M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | ADD | 82,645 | 134,015 | +62.2% | $6.5M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 83,052 | 109,638 | +32.0% | $5.3M | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 35,053 | 75,301 | +114.8% | $3.6M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 168,584 | 69,107 | -59.0% | $3.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 115,200 | 55,800 | -51.6% | $2.7M | 2026-Q1 |
| Brevan Howard Capital Management LP | TRIM | 86,310 | 47,266 | -45.2% | $2.2M | 2026-Q1 |
| BANK OF MONTREAL /CAN/ | TRIM | 54,341 | 39,984 | -26.4% | $1.9M | 2026-Q1 |
| Verition Fund Management LLC | TRIM | 78,149 | 28,074 | -64.1% | $1.4M | 2026-Q1 |
| STIFEL FINANCIAL CORP | DOUBLED | 4,830 | 11,342 | +134.8% | $546.7K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 26,274 | 10,701 | -59.3% | $515.8K | 2026-Q1 |
| Allianz Asset Management GmbH | TRIM | 12,000 | 8,600 | -28.3% | $414.5K | 2026-Q1 |
| DnB Asset Management AS | TRIM | 12,639 | 8,188 | -35.2% | $394.7K | 2026-Q1 |
| Independent Advisor Alliance | ADD | 4,543 | 7,444 | +63.9% | $358.8K | 2026-Q1 |
| Jain Global LLC | NEAR_EXIT | 99,996 | 5,772 | -94.2% | $278.2K | 2026-Q1 |
| Invesco Ltd. | ADD | 3,200 | 4,581 | +43.2% | $220.8K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 3,926 | 2,854 | -27.3% | $137.6K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 731 | 2,220 | +203.7% | $107.0K | 2026-Q1 |
8 unique insiders with 22 transactions. Net insider value: -$75.3K ($0.00 bought, $75.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Lang Matthew | COO & GC | AWARD | 223,776 | — | — |
| Apr 15, 2026 | Lang Matthew | COO & GC | AWARD | 184,614 | — | — |
| Apr 14, 2026 | FMR LLC | 10%+ Owner | SELL | 1,367 | $55.07 | $75.3K |
| Mar 19, 2026 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | AWARD | 322,230 | — | — |
| Mar 19, 2026 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | AWARD | 260,217 | — | — |
| Mar 19, 2026 | Yoon Jun | CHIEF FINANCIAL OFFICER | AWARD | 104,085 | — | — |
| Mar 19, 2026 | Hall Ashley | Chief Development Officer | AWARD | 47,706 | — | — |
| Mar 19, 2026 | Hall Ashley | Chief Development Officer | AWARD | 59,073 | — | — |
| Mar 19, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | AWARD | 93,984 | — | — |
| Mar 19, 2026 | Coll Crespo Blas | CHIEF MEDICAL OFFICER | AWARD | 75,897 | — | — |
| Mar 19, 2026 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | AWARD | 32,526 | — | — |
| Mar 19, 2026 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | AWARD | 40,278 | — | — |
| Mar 19, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | AWARD | 43,368 | — | — |
| Mar 19, 2026 | Lin Xichen | CHIEF SCIENTIFIC OFFICER | AWARD | 53,703 | — | — |
| Mar 19, 2026 | Yoon Jun | CHIEF FINANCIAL OFFICER | AWARD | 128,892 | — | — |
| Mar 3, 2026 | Yoon Jun | CHIEF FINANCIAL OFFICER | TAX W/H | 22,305 | $20.99 | $468.2K |
| Mar 3, 2026 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | TAX W/H | 53,454 | $20.99 | $1.1M |
| Mar 3, 2026 | Ma Yingli | CHIEF TECHNOLOGY OFFICER | TAX W/H | 11,313 | $20.99 | $237.5K |
| Mar 3, 2026 | Hall Ashley | Chief Development Officer | TAX W/H | 4,836 | $20.99 | $101.5K |
| Nov 20, 2025 | Hall Ashley | Chief Development Officer | AWARD | 237 | — | — |
| Nov 20, 2025 | Stevens Raymond C | CHIEF EXECUTIVE OFFICER | AWARD | 824 | — | — |
| May 20, 2025 | Hall Ashley | Chief Development Officer | AWARD | 225 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 2 mixed, 1 neutral. Avg impact: 5.0/10.
BEARISH
INST-CLUSTER
5/10
A mixed institutional cluster in GPCR (2025-Q3) shows 4 buyers adding a net $6.0M against 3 sellers
Jun 11, 2026
MIXED
8-K
6/10
Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while a
May 7, 2026
NEUTRAL
8-K
3/10
Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effect
Apr 15, 2026
MIXED
INST-CLUSTER
6/10
In Q4 2025, three mega-passive institutions—Fidelity, Morgan Stanley, and BofA—significantly increas
Feb 28, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 24 analysts: 8 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$104.59 mean target
+143.6% upside
Strong Buy (1.38)
$69.50 Low
$145.00 High
| Metric | Value |
|---|---|
| Current Price | $42.93 |
| Target Low | $69.50 |
| Target Mean | $104.59 |
| Target Median | $101.00 |
| Target High | $145.00 |
| # Analysts | 16 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.38 | $-0.47 | $-0.20 | -6.1% | — | 1↑ 0↓ | $0.0B | 0.0% | 10 |
| Next Q 2026-09-30 |
$-0.19 | $-0.49 | $2.03 | 49.5% | — | 0↑ 1↓ | $0.1B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-1.43 | $-1.93 | $1.25 | -78.8% | — | 5↑ 3↓ | $0.0B | 0.0% | 12 |
| Next FY 2027-12-31 |
$-2.08 | $-3.08 | $-1.34 | -45.3% | — | 4↑ 3↓ | $0.0B | -99.9% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.382 | |
| 7d ago | $-0.372 | -0.010 |
| 30d ago | $0.000 | -0.382 |
| 60d ago | $-0.444 | +0.062 |
| 90d ago | $-0.437 | +0.055 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 16, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Jan 22, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| May 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 8 | 13 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 22, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 5, 2026
fda
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
<p align="center"><em>Publication presented concurrently with oral presentation at</em><br><em> American Diabetes Association’s 86th Scientific Sessio
May 26, 2026
other
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
<p align="left">SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutica
May 6, 2026
earnings_calendar
GPCR Q1 2026 Earnings After Market Close — 2026-05-06
Apr 27, 2026
fda
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
<p align="left">SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceuti
Apr 15, 2026
short_interest
FTD: GPCR — 111,564 shares ($5.9M) failed to deliver
Settlement: 20260415, Price: $53.22, FTD Value: $5,937,436.08, STRUCTURE THERAPEUTICS INC SPO
Apr 14, 2026
other
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
<p>SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company d
Apr 13, 2026
short_interest
FTD: GPCR — 152,914 shares ($8.3M) failed to deliver
Settlement: 20260413, Price: $54.51, FTD Value: $8,335,342.14, STRUCTURE THERAPEUTICS INC SPO
Apr 2, 2026
short_volume
Short Volume: GPCR — 62.7% short (0.5M / 0.7M)
Short: 457,033 | Exempt: 252 | TRF Vol: 728,938 | Short Ratio: 62.7% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_volume
Short Volume: GPCR — 62.8% short (0.4M / 0.6M)
Short: 372,176 | Exempt: 0 | TRF Vol: 592,729 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: GPCR — 61.9% short (0.4M / 0.6M)
Short: 386,867 | Exempt: 1,501 | TRF Vol: 624,953 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: GPCR — 56.5% short (0.4M / 0.8M)
Short: 429,872 | Exempt: 21,347 | TRF Vol: 760,385 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Mar 16, 2026
fda
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
<p align="center"><em>Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg </em><em>at 44 weeks with no evidence
Feb 25, 2026
earnings_calendar
GPCR Q4 2025 Earnings After Market Close — 2026-02-25
Feb 6, 2026
short_interest
FTD: GPCR — 23,325 shares ($1.7M) failed to deliver
Settlement: 20260206, Price: $73.21, FTD Value: $1,707,623.25, STRUCTURE THERAPEUTICS INC SPO